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Abstract: Fructus schisandrae (Wuweizi in Chinese), a common traditional Chinese herbal medicine,
has been used for centuries to treat chronic liver disease. The therapeutic efficacy of Wuweizi has also
been validated in clinical practice. In this study, molecular docking and network analysis were carried
out to explore the hepatoprotective mechanism of Wuweizi as an effective therapeutic approach
to treat liver disease. Multiple active compounds of Wuweizi were docked with 44 protein targets
related with viral hepatitis, fatty liver, liver fibrosis, cirrhosis, and liver cancer. A compound–target
network was constructed through network pharmacology analysis, predicting the relationships
of active ingredients to the targets. Our results demonstrated that schisantherin, schisandrin B,
schisandrol B, kadsurin, Wuweizisu C, Gomisin A, Gomisin G, and angeloylgomisin may target with
21 intracellular proteins associated with liver diseases, especially with fatty liver disease. The CYP2E1,
PPARα, and AMPK genes and their related pathway may play a pivotal role in the hepatoprotective
effects of Wuweizi. The network pharmacology strategy used provides a forceful tool for searching
the action mechanism of traditional herbal medicines and novel bioactive ingredients.
Keywords: Wuweizi; network pharmacology; hepatoprotective effect
1. Introduction
Liver diseases, including viral hepatitis, fatty liver, liver fibrosis, cirrhosis, and liver cancer,
are major diseases threatening human health and are the leading cause of deaths worldwide [1].
Although there has been remarkable progress in the treatment of liver diseases over the last several
decades, most of the therapies still do not yield satisfactory outcomes in patients [2]. In view of the
scarce treatment options and significant adverse effects caused by conventional chemical agents, novel
prophylactic and therapeutic agents against liver disease are urgently needed [3].
Fructus schisandrae (Wuweizi in Chinese), the fruit of Schisandra chinensis (Turcz.) Baill.,
is a traditional herbal medicine, which is believed to be liver tonic in China, Japan, and Russia [4].
According to the theories of traditional Chinese medicine (TCM), Wuweizi can be used for treating
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Liver and Kidney Deficiency of Yin or Yang syndrome [5]. Modern pharmacological study showed
that Wuweizi might exhibit various therapeutic effects, such as hepatoprotection, anti-inflammation,
and antioxidant properties [4,6–8]. Recent studies demonstrated that the extract from Wuweizi could
alleviate hepatic cholesterol and triglyceride levels, and retard the development of fatty liver in rodents
given high-fat diets [9]. Wuweizi extract could also attenuate mitochondrial Ca2+ loading and reduce
the sensitivity of hepatic mitochondria to Ca2+-dependent MPT caused by carbon tetrachloride [10].
In addition, Wuweizi could enhance both mitochondrial and cellular glutathione levels and antioxidant
status by mediating glutathione synthesis and GPx levels, thus reducing ROS and protecting the tissues
from oxidative stress in both in vitro and in vivo studies. Although several potential active components
of Wuweizi have been reported, a holistic understanding of the molecular mechanisms responsible for
their hepatoprotective effects still needs further exploration.
To comprehensively assess herbal pharmacological effects, network pharmacology has been
introduced in recent years for exploring the molecular mechanisms of TCMs [11,12]. With a deeply
curated network map that describes interactions among molecules, researchers can carry out
network-based screening to systematically identify target proteins of herbal medicines and to assess
their impacts. Thus, network-based screening appears promising for secondary development of
traditional Chinese herbal medicines and mechanisms prediction. Various bioinformatics resources
including biological databases and molecular docking software have been developed in recent years,
allowing a great opportunity for meeting the demands of rapid systematic screening [13–15]. In this
study, a network pharmacology study of Wuweizi was established through molecular docking and
network analysis based on current identified active components of Wuweizi and potential targets
associated with liver diseases. The study may provide a powerful tool for exploring the active
mechanisms of TCMs and discovering novel bioactive ingredients of Wuweizi.
2. Results and Discussion
2.1. Potential Biological Effect of Fructus Schisandrae on Liver Disease Predicted by Network
Pharmacological Analysis
In multi-compound medicinal herbs like Wuweizi, many compounds that lack appropriate
pharmaceutical properties are believed to fail in reaching the cellular targets; thus, these compounds
exhibit limited efficacy that can be neglected. We have identified a total of 117 potentially active
chemicals in Wuweizi (Table S1). The targets of these active chemicals of Wuweizi were predicted
through molecular docking. To further illuminate the relationship between the effective compounds
and potential targets, a compound–target network was built through network analysis. The compound
and protein interaction analysis results showed that a total of 21 intracellular targets were predicted
to interact with the 8 ingredients of Wuweizi (Figure 1). This network represents a global view of
the potential compounds (pink triangles) and targets (blue rectangles) in Wuweizi, and it comprised
29 nodes (8 potential compounds and 21 potential targets) and 46 edges (compound–target interactions).
The degree of nodes is a key topological parameter that characterizes the most influential nodes in
a network, and we used it to further determine the importance of active components and liver
disease targets [16,17]. Those high-degree nodes in the network, which had more compound–target
interactions, are likely to play a more important role in liver diseases [16]. Our network analysis
results showed that various candidate compounds in Wuweizi were linked to multiple targets, which
might exhibit potent hepatoprotective effects. Among the 8 candidate compounds, schisantherin A
exhibited the largest number of potential hepatoprotective targets connections (degree = 9), followed by
schisandrin B (degree = 6), schisandrol B (degree = 6), kadsurin (degree = 4), wuweizisu C (degree = 4),
gomisin A (degree = 4), gomisin G (degree = 2), and angeloylgomisin (degree = 1). For the 21 potential
hepatoprotective targets, the network showed CYP2E1 had the largest number of compound–target
interactions (schisandrin B, kadsurin, schisantherin A, wuweizisu C, gomisin A, and gomisin G),
followed by PPARα (schisantherin A, wuweizisu C, and gomisin A), and AMPK (angeloylgomisin,
gomisin A, and gomisin G). The remaining 18 targets showed interactions with only one or two
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compounds. The information of 21 potential hepatoprotective targets in Wuweizi can be found in
Table 1, where all the data were manually collected and integrated from the STITCH, TTD, PharmGKB,
and CTD databases. For the 8 potential active chemicals in Wuweizi, some of them have been
confirmed by experimental studies. For example, schisandrol B and kadsurin can inhibit CYP2E1
in rat primary hepatocytes and oxidize xenobiotics, such as toxins or drugs, and remove them from
the body [18]. Schisantherin A treatment can suppress the enzymatic activities of several CYP450
isoforms, which are related to acetaminophen bioactivation, such as CYP2E1, CYP1A2, and CYP3A11,
and further decreased the formation of acetaminophen toxic intermediate N-acetyl-p-benzoquinone
imine (NAPQI) in mouse microsomal incubation system. This study demonstrated that schisantherin A
exhibited significant protective actions toward acetaminophen-induced liver injury, which was partially
associated with the inhibition of CYP-mediated acetaminophen bioactivation [19]. A recent study
showed that gomisin A exhibited significant anti-hepatotoxic action by oral application, hypolipidemic
(mainly triglyceridemic) and liver protein synthesis-facilitating actions. The enlargement of the liver
seen with treatment of gomisin A is the adaptive hypertrophy, which is due to the induction of
drug-metabolizing enzymes [20]. In addition, administration of gomisin G to high-fat-diet-induced
obese mice decreased liver weight, hepatic triglyceride (TG) accumulation, and cytoplasmic lipid
droplets. These findings demonstrate that Gomisin activated the AMPK pathway and ameliorated
HFD-induced hepatic steatosis [21]. Wuweizisu C has also been widely studied by previous researches.
It could dose-dependently inhibit fatty degeneration and decrease serum triglyceride. These researches
suggested that wuweizisu C could be protective on hepatocellular phenomena such as cell necrosis,
fatty degeneration, inflammatory cell infiltration, etc., on human hepatitis [22]. Wuweizisu C also
exhibited remarkable antihepatotoxic effects in CCl4-induced cytotoxicity, indicating that anti-oxidative
action plays an important role in the antihepatotoxic activity of wuweizisu C and Wuweizi [23].
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Table 1. Forty-four protein targets related with viral hepatitis, fatty liver, liver fibrosis, cirrhosis, and
liver cancer.
Target Gene Target Protein Roles in Hepatoprotective Effects
HLA-DRB1 major histocompatibility complex, class II,DQ beta 1 Anti-virus
IFNL3 interferon lambda 3 Anti-virus
HLA-DRB5 major histocompatibility complex, class II,DQ beta 5 Anti-virus
IL6 Interleukin 6 Anti-virus
NAT2 N-acetyltransferase 2 Reduce antituberculosis drug-induced liver injury
STAT3 signal transducer and activator oftranscription 3 Regulate hepatic cell growth and apoptosis
CYP2C9 Cytochrome P450 2C9 Regulate drug metabolism
CYP2D6 Cytochrome P450 2D6 Regulate drug metabolism
CYP3A Cytochrome P450 3A Regulate drug metabolism
ITPA inosine triphosphate pyrophosphatase Regulate drug metabolism
UGT1A1 UDP glucuronosyltransferase family 1member A1 Regulate drug metabolism
UGT1A3 UDP glucuronosyltransferase family 1member A3 Regulate drug metabolism
CYP2E1 Cytochrome P450 2E1 Regulate drug metabolism
HSPA1L Heat shock 70 kDa protein 1L Regulate drug metabolism
CYP2C19 Cytochrome P450 C19 Regulate drug metabolism
PEMT phosphatidylethanolamineN-methyltransferase Regulate drug metabolism
PNPLA3 Patatin-like phospholipasedomain-containing protein 3 Regulate fatty metabolism
AKT1 v-akt murine thymoma viral oncogenehomolog 1 Regulate lipid metabolism
CYP2B6 cytochrome P450, family 2, subfamily B,polypeptide 6
Oxidizes a variety of structurally unrelated
compounds, including steroids, fatty acids
CYP1B1 cytochrome P450, family 1, subfamily B,polypeptide 1
Oxidizes a variety of structurally unrelated
compounds, including steroids, fatty acids
MMP2 matrix metallopeptidase 2 Tissue repair and induce interstitial fibrosis
PPARα peroxisome proliferator-activatedreceptor alpha Key regulator of lipid metabolism
NFKBIA nuclear factor of kappa light polypeptidegene enhancer in B-cells inhibitor, alpha
On cellular stimulation by immune and
proinflammatory responses
AHSA1 activator of heat shock 90kDa proteinATPase homolog 1
Involve in Grb2-p38 MAPK signaling pathway
in fibrosis
NQO1 NAD(P)H dehydrogenase, quinone 1 Involve in alcohol detoxification pathways
HMOX1 heme oxygenase (decycling) 1 Alleviate liver inflammation and reducedoxidative stress
ICAM-1 intercellular adhesion molecule 1 Mediate adhesive interaction in fibrosis process
MAPK1 mitogen-activated protein kinase 1 Regulate cytoskeletal rearrangements infibrosis process
PRKCB protein kinase C, beta Regulate oxidative stress-induced cell damage
ACTA2 actin, alpha 2, smooth muscle, aorta Involve in myofibroblast cell motility duringwound healing in liver
SPZ1 spermatogenic leucine zipper 1 The transcriptional factors of liver fatty acidbinding protein
COL1A1 collagen, type I, alpha 1 Transcriptional repressor of the collagen
BCL2 B-cell CLL/lymphoma 2 Regulate the response to mitochondrial damageand related oxidative damage
CCND1 cyclin D1 Functions as a mediator of β-catenin duringhepatocarcinogenesis
RKIP Raf kinase inhibitor protein Regulate carbon tetrachloride-induced apoptotichepatic cell death
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Table 1. Cont.
Target Gene Target Protein Roles in Hepatoprotective Effects
HERC5 HECT and RLD domain containing E3ubiquitin protein ligase 5
Acts as a positive regulator of innate antiviral
response in liver cells
CDKN1A cyclin-dependent kinase inhibitor 1A Regulate hepatic cell cycle in hepatocarcinogenesis
mTOR mammalian target of rapamycin Regulate hepatic cell autophagy
EIF6 eukaryotic translation initiation factor 6 Regulate hepatocarcinogenesis by mediatingcellular response to DNA damage.
CASP3 caspase 3 Apoptosis inhibitory protein inhepatocarcinogenesis
COL7A1 collagen, type VII, alpha 1 Regulate fibrosis by impacts on extracellular matrix(ECM) proteins such as type IV collagen
COL3A1 collagen, type III, alpha 1 Regulate fibrosis by impacts on extracellular matrix(ECM) proteins such as type IV collagen
HSP 25 25 kilodalton heat shock proteins Protect cells from oxidation stress
TGFB1 transforming growth factor, beta 1 Regulate liver cancer cells proliferation
TIMP1 TIMP metallopeptidase inhibitor 1 Tissue repair and induce interstitial fibrosis
SOD1 superoxide dismutase 1 Destroys radicals that are normally producedwithin the cells, such as oxidants
RELA v-rel reticuloendotheliosis viral oncogenehomolog A Involve in hepatic inflammation
PCNA Proliferating Cell Nuclear Antigen Inhibit HCC cell proliferation
XBP-1 X-box-binding protein-1 Protection against endoplasmic reticulum(ER) stress
AMPK AMP-activated protein kinase Regulate hepatic fatty acid oxidation
The compound–target network related to hepatoprotective mechanism of Wuweizi in liver
disease was shown in the network plotting. This network represents a global view of the potential
compounds (pink triangles) in Wuweizi and their intracellular targets (blue rectangles) for liver disease.
The network comprised 29 nodes (8 potential compounds and 21 potential targets) and 46 edges
(compound–target interactions).
2.2. Potential Hepatoprotective Molecular Mechanism of Wuweizi
The potential hepatoprotective mechanisms of Wuweizi were further analyzed by above network
pharmacology study. Our results demonstrated that multiple components in Wuweizi could target
various intracellular genes associated with liver diseases, especially for fatty liver disease (Figure 2).
CYP2E1, the key node in our network plotting, may play a pivotal role in hepatoprotective effects
of Wuweizi. Previous studies showed that several risk factors such as alcohol and toxics could
induce CYP2E1 activation and further increase hepatic oxidative stress [24]. The reactive oxygen
species (ROS) generated by CYP2E1 may lead to the production of reactive aldehydes with potent
pro-inflammatory properties [25]. Oxidative stress increases NF-κB activation, thus enhancing the
expression of COX-2 and iNOS. The upregulation of COX-2 expression causes the enhanced production
of PGE2, which functions through its receptors (EP2 and/or EP4) in hepatocytes to increase the
accumulation of triglycerides and further promote the development of fatty liver disease [26,27].
Furthermore, CYP2E1 may be directly associated with the development of drug-induced liver injury
during oxidative stress. Inhibiting CYP2E1 activity resulted in a decrease in the production of
reactive oxygen species (ROS) during thioacetamide (TAA) [28] or isonicotinyl hydrazine (INH)
metabolism [29]. Thus, the regulation of CYP2E1 activity by Wuweizi (schisandrin B, kadsurin,
schisantherin A, wuweizisu C, gomisin A, and gomisin G) may inhibit hepatic lipid peroxidation and
alleviate hepatic injury.
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Figure 2. Schematic illustrating proposed potential hepatoprotective mechanisms of Wuweizi.
The network results demonstrated that multiple components in Wuweizi can target various
intracellular genes associated with liver disease, especially for fatty liver disease. The CYP2E1,
PPARα, and AMPK genes and related pathway may play a pivotal role in the hepatoprotective effects
of Wuweizi.
Peroxisome proliferator-activated receptor alpha (PPARα), another key node in our network
pharmacology study, can modulate lipid peroxidation in fatty liver disease. PPARα is a kind of
nuclear receptor proteins, and important transcription factors in the regulation of some enzymes
in the β-oxidation pathway. Previous studies showed that PPARα expression was downregulated
in alcoholic liver disease (ALD) and non-alcoholic fatty liver disease (NAFLD) in human liver [30].
Activating PPARα in liver can also prevent acetaminophen-induced liver damage by upregulating
mitochondrial glutathione and downregulating fatty acyl-carnitines concentration in blood [31].
In addition, during chronic alcoholic liver injury, PPARα also protects liver tissue by activating
fatty acid β-oxidation related pathway [30]. Although PPARα has no direct effects to hepatic lipid
metabolism, the transcription level of several PPARα downstream target genes such as acyl-CoA
oxidase (ACO) and carnitine palmitoyltransterase-1 (CPT-1) may play a critical role in preventing
ALD and NAFLD by regulating mitochondrial and fatty acid β-oxidation [32]. In addition, PPARα can
induce a high expression of Acyl-CoA Oxidase (ACO) and carnitine palmitoyltransferase 1 (CPT-1)
in adipose tissue and improve glucose homeostasis [33]. Previous studies showed that Wuweizi
extract prevented the ethanol-induced decrease in PPARα expression and resulted in a significant
decrease in intracellular lipid accumulation in hepatocytes along with a decrease in serum TG levels,
and it reversed fatty liver to normal conditions [34]. Our network pharmacology study indicated that
the potential active components of Wuweizi such as schisantherin A, wuweizisu C, and gomisin A
may exhibit preventive ability for fatty liver disease through modulating the activity of PPARα and
regulating the expression of several key genes in mitochondrial and fatty acid β-oxidation [35].
AMP-activated protein kinase (AMPK) may also play a major role in the control of hepatic injury
by Wuweizi according to our network results. AMPK integrates nutritional and hormonal signals
to promote energy balance by switching on catabolic pathways and switching off ATP-consuming
pathways, both by short-term effects on phosphorylation of regulatory proteins and by long-term
effects on gene expression. Activating AMPK in liver leads to the stimulation of fatty acid oxidation
and inhibition of lipogenesis, glucose production as well as protein synthesis [36]. A previous
study showed that enhanced phosphorylation of AMPK can inhibit the accumulation and nuclear
translocation of mature sterol regulatory element-binding protein 1 (SREBP-1) and subsequently
decreased the mRNA levels of lipogenic genes including acc1, fas, and scd1 [37]. Another study
also confirmed that the decreased phosphorylation of AMPK could increase maturation of SREBP-1
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and expression of SREBP-responsive genes in the rat liver, and thus inhibit lipid accumulation in rat
hepatocytes and human hepatoma cell lines [38]. Activating the phosphorylation levels of AMPK can
also inhibit Acetyl-CoA Carboxylase (ACC) and increase CPT-1 expression to reduce hepatic lipid
accumulation [39]. In addition, activation of AMPK can reduce the expression of hepatocyte nuclear
factor 4α (HNF-4α) and decrease hepatic fatty acid synthesis [40].
Some of the in silico data in our study have been further checked and proved by previous
experimental data based on literature research. For example, a recent study results of Western blot
indicated that schisandrin B can inhibit cell proliferation by downregulating proliferating cell nuclear
antigen (PCNA) and induce cell apoptosis in HCC cells [41]. Incubation with schisandrin B for 6 h
caused optimal and dose-dependent increases in cellular 25 kilodalton heat shock proteins (Hsp25)
activation at 16 h post-drug exposure in AML12 hepatocytes [42]. Another study found that gomisin
A could activate AMP-activated protein kinase (AMPK) and exerts therapeutic effects on liver X
receptor (LXR)- or palmitic acid (PA)-induced triglyceride (TG) accumulation in HepG2 cells [21].
These biological results further confirmed the potential prospects of our in silico method in exploring
the hepatoprotective mechanisms of Wuweizi.
3. Materials and Methods
3.1. Database Construction and ADME Screening of Wuweizi Ingredients
All of the known ingredients of Wuweizi were manually collected from related literature
and two phytochemical databases: Traditional Chinese Medicine Systems Pharmacology Database
(TCMSP, http://ibts.hkbu.edu.hk/LSP/tcmsp.php) and TCM Database@Taiwan (http://tcm.cmu.
edu.tw/). An in silico integrative model~ADME was used to select the ingredients with favorable
pharmacokinetics properties. The ADME system used in this study included oral bioavailability
(PreOB) and Caco-2 permeability (PreCaco-2) prediction. Oral bioavailability (OB) is one of the
most vital pharmacokinetic properties of orally administered drugs as it plays an important role
for the efficiency of the drug delivery to the systemic circulation [43,44] Here, a reliable in silico
screening model (OBioavail 1.1) was employed in OB value calculation of the constituents in Wuweizi.
This model was constructed based on 805 structurally diverse drugs and drug-like molecules.
Multiple linear regression, partial least square, and support vector machine methods were applied
during this model building, ending up with determination coefficient (R2) = 0.80 and standard error
of estimate (SEE) = 0.31 for test sets [45,46]. In addition, for orally administered drugs, another
pivotal problem is their movement across the intestinal epithelial barrier, which determines the rate
and extent of human absorption and ultimately affects its bioavailability [47]. Thus, a preCaco-2
model was used to predict the drug absorption. The phytochemical information of the compounds
with their Caco-2 permeability properties were explored using the TCMSP database, the detailed
parameters’ information, screening criteria, and calculation can be obtained from TCMSP website
(http://ibts.hkbu.edu.hk/LSP/tcmsp.php). Finally, compounds values where OB ≥ 30% and
Caco2 ≥ 0.4 cm/s were regarded as active ingredients for further study. It is worth noting that
the OB value of schisantherin A and schisandrin B are lower than 30%, but both of them have been
widely expected to be the active components in Wuweizi [48–50]. Thus, these two compounds were
also regarded as bioactive compounds for further analysis.
3.2. Preparation of Potential Targets and Ligand Structures
The candidate proteins related to liver diseases were data-mined from literatures and public
database sources, including PubMed (www.PubMed.org), PubChem (www.Pubchem.org), DrugBank
(http://www.drugbank.ca/), Potential Drug Target Database (http://www.dddc.ac.cn/pdtd/),
Therapeutic Targets Database (http://bidd.nus.edu.sg/group/ttd/) and PharmGkb (www.pharmgkb.
org). As of today, up to 44 protein targets related to viral hepatitis, fatty liver, liver fibrosis, cirrhosis
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and liver cancer were obtained (Table 1), and their corresponding X-ray crystallographic structures
were directly downloaded from RCSB Protein Data Bank (http://www.pdb.org/).
3.3. Molecular Docking and Network Building
All the docking studies were carried out using the protein–ligand complexes with crystal
structures. Prior to the docking studies, the protein structures were prepared with Sybyl-X version
2.0 software (Tripos Associates Inc., St. Louis, MO, USA) [51]. The preparation work includes
affixing hydrogen atoms and removing co-crystallized ligands as well as water molecules from the
protein–ligand complexes. All the amide moieties of glutamine and asparagine in the side chains
were regulated to modify their connections with nearby residues and atoms. Then, we used the
Surflex-Dock module of Sybyl-X to continue docking. The detailed docking operation process
and reliability-validated assay strictly followed the software instruction manual. The targets
with docking consensus score greater than 6.0 were selected as the potential targets for further
analysis [52–54]. The compound–target network was then constructed using Cytoscape 3.0.2 software
(http://www.cytoscape.org/) based on the molecular docking score. In the network, nodes stand for
compounds and targets, and edges represent the compound–target interactions.
4. Conclusions
In this study, a compound–target network was constructed through molecular docking and
network analysis. The network predicted the underlying mechanism of hepatoprotective effect of
Wuweizi as a therapeutic approach to treat liver diseases, especially for fatty liver disease. This study
demonstrated that a network pharmacology-based approach was useful for elucidation of the
interrelationship between complex diseases such as liver diseases and Chinese herbal medicines
interventions. Therefore, network pharmacology is a powerful tool for exploring the potential action
mechanism of TCMs and new active ingredients. However, the current molecular docking results in
our network pharmacology studies only provide indeterminate connections between chemicals and
corresponding target genes. The accurate action modes between chemicals and target genes such as
activation or inhibition are still not clear. To resolve this problem, experimental verification of the
potential effective compounds after candidate screening is needed to validate the interactions between
drugs and proteins based on theoretical predictions.
Supplementary Materials: Supplementary Materials are available online. Table S1: 117 potential active chemicals
in Wuweizi.
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